Companies priced their initial public offerings (IPOs) in two hot therapeutic spaces, immunotherapy and biosimilars, proving that the window remains open – at least for the right candidates, if not at the hoped-for yield. But another firm withdrew its IPO, which could mean tighter times ahead.